New drug cocktail aims to help myeloma patients with kidney failure
NCT ID NCT04240054
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of four drugs (bortezomib, isatuximab, cyclophosphamide, and dexamethasone) as an initial treatment for people with multiple myeloma who also have kidney problems and are eligible for a stem cell transplant. The goal is to see how well this drug combo shrinks the cancer before transplant. About 41 participants will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Froedtert Hospital & the Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact